Close
Smartlab Europe
Inizio Ignite

News

BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years

BD, a leading global medical technology company, announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across its six...

New destinations for life-saving pharmaceutical products

DoKaSch Temperature Solutions and Air Europa have signed a Master Rental Agreement about the usage of the temperature-controlled Opticooler packaging solution. The collaboration opens up important new direct routes between Europe and Latin America. Until now, several destinations could...

UK Approves Pfizer COVID-19 Vaccine: Expect A Next Week Roll-Out

In a historic occurrence which has taken the world by storm, the UK Government has officially approved the usage of Pfizer’s coronavirus vaccine. This move may bring a lot of intensity to other countries and their respective regulators too....

Kuehne+Nagel and Qatar Airways Cargo donate freight services to support global Covid-19 response

As part of the “1 million kilos” charitable initiative, Kuehne+Nagel and Qatar Airways Cargo donate air freight services to UNICEF, supporting the agency’s global efforts in the fight against the Covid-19 pandemic. Triggered by the Covid-19 crisis, the “1 million...

Russia’s Sputnik V likely to be available for supply from January

Russia's Sputnik-V COVID-19 vaccine might become available for supply as early as next month, the country's sovereign wealth fund RDIF's top official told ThePrint. According to Kirill Dmitriev, the Chief Operating Officer (COO) of RDIF, they are hoping for approval...

Russia to present Sputnik V vaccine against coronavirus at United Nations

Russia's permanent mission to the UN and the Health Ministry will hold a presentation, which will provide detailed information on the Russian vaccine against the novel coronavirus disease (COVID-19), mission spokesman Fyodor Strzhizhovsky told Sputnik. During a speech at the...

Algernon completes patient enrollment in phase 2b/3 study of Ifenprodil to treat COVID-19

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that the final patient has been enrolled in its multinational phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19. The aggregate total number of patients enrolled from...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »